Publications by authors named "Katsutoshi Inagaki"
Article Synopsis
- The study aimed to assess how effective once-daily (QD) versus twice-daily (BID) dosing of budesonide foam is in treating ulcerative colitis (UC) and achieving symptom resolution.
- Data from phase 2 and phase 3 clinical trials showed that patients receiving BID had a significantly higher early response rate and better endoscopic remission compared to those on QD or placebo.
- Overall, the findings suggest that a BID regimen of budesonide is more effective for early responders and leads to improved outcomes after treatment cessation.
Article Synopsis
- The study focused on the impact of twice-daily budesonide foam enema on bowel urgency in patients with mild-to-moderate ulcerative colitis (UC), highlighting its importance for quality of life.
- Over a 4-week period, 61 patients reported their symptoms, with results showing a 58.5% resolution rate of bowel urgency and a clinical remission rate of 64.4%.
- The treatment was generally safe, with only one adverse event unrelated to the medication, indicating early improvement in bowel urgency without new safety concerns.
Background: Budesonide foam is effective in inducing clinical remission in ulcerative colitis (UC) patients with active proctosigmoiditis. The aim of this study was to evaluate the duration of remission and predictors of relapse in UC patients who achieved clinical remission and mucosal healing by 6-week treatment with topical budesonide.
Methods: This is a retrospective, observational, multicenter study with a 2-year follow-up period.